跳至主要内容
临床试验/EUCTR2020-003987-22-DE
EUCTR2020-003987-22-DE进行中(未招募)1 期

ORACLE: A long-term follow-up study to evaluate the safety of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study. - ORACLE

Gyroscope Therapeutics Ltd.0 个研究点目标入组 225 人开始时间: 2022年7月13日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
225

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Able and willing to give written informed consent
  • 2. Received GT005 in an antecedent study, GT005-01 (FOCUS, NCT03846193), GT005-02 (EXPLORE, NCT04437368 and GT005-03 (HORIZON, NCT04566445)
  • 3. Willing to attend study visits and complete the study procedures.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 23
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 202

排除标准

  • Not Applicable.

研究者

相似试验

招募中
1 期
Study to evaluate the long term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and that have been previously treated in a prior Gyroscope study using the same product.Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent studies.MedDRA version: 20.0Level: LLTClassification code 10075719Term: Atrophic age-related macular degenerationSystem Organ Class: 100000004853
EUCTR2020-003987-22-NLGyroscope Therapeutics Ltd.200
进行中(未招募)
1 期
Study to evaluate the long term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and that have been previously treated in a prior Gyroscope study using the same product.Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent studies.MedDRA version: 20.0Level: LLTClassification code 10075719Term: Atrophic age-related macular degenerationSystem Organ Class: 100000004853
EUCTR2020-003987-22-ESGyroscope Therapeutics Ltd.200
撤回
2 期
ORACLE: A long-term follow-up study to evaluate the safety and durability of GT005 in participants with geographic atrophy, secondary to age-related macular degeneration treated in a Gyroscope-sponsored antecedent study.
NL-OMON56154Gyroscope Therapeutics Ltd.15
进行中(未招募)
1 期
Study to evaluate the long term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and that have been previously treated in a prior Gyroscope study using the same product.Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent studies.MedDRA version: 20.0Level: LLTClassification code 10075719Term: Atrophic age-related macular degenerationSystem Organ Class: 100000004853
EUCTR2020-003987-22-IEGyroscope Therapeutics Ltd.300
进行中(未招募)
1 期
Study to evaluate the long-term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and that have been previously treated in a prior Gyroscope study using the same product.Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).MedDRA version: 20.0Level: LLTClassification code: 10075719Term: Atrophic age-related macular degeneration Class: 10015919
CTIS2024-510946-15-00Gyroscope Therapeutics Limited163
Study to evaluate the long term safety of GT005 in... | 临床试验